Early access to medicines scheme (EAMS) scientific opinion: Abrocitinib for treatment of adult and adolescent patients with severe atopic dermatitis

Positive opinion issued for treatment of severe atopic dermatitis requiring treatment with systemic therapy; which has had inadequate response or have lost response to approved systemic therapies, or those who are ineligible or intolerant of approved systemic therapies.

Source:

Medicines and Healthcare products Regulatory Agency